These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

478 related items for PubMed ID: 24199682

  • 1. Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer.
    Yamaguchi N, Lucena-Araujo AR, Nakayama S, de Figueiredo-Pontes LL, Gonzalez DA, Yasuda H, Kobayashi S, Costa DB.
    Lung Cancer; 2014 Jan; 83(1):37-43. PubMed ID: 24199682
    [Abstract] [Full Text] [Related]

  • 2. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.
    Sasaki T, Koivunen J, Ogino A, Yanagita M, Nikiforow S, Zheng W, Lathan C, Marcoux JP, Du J, Okuda K, Capelletti M, Shimamura T, Ercan D, Stumpfova M, Xiao Y, Weremowicz S, Butaney M, Heon S, Wilner K, Christensen JG, Eck MJ, Wong KK, Lindeman N, Gray NS, Rodig SJ, Jänne PA.
    Cancer Res; 2011 Sep 15; 71(18):6051-60. PubMed ID: 21791641
    [Abstract] [Full Text] [Related]

  • 3. Amphiregulin triggered epidermal growth factor receptor activation confers in vivo crizotinib-resistance of EML4-ALK lung cancer and circumvention by epidermal growth factor receptor inhibitors.
    Taniguchi H, Takeuchi S, Fukuda K, Nakagawa T, Arai S, Nanjo S, Yamada T, Yamaguchi H, Mukae H, Yano S.
    Cancer Sci; 2017 Jan 15; 108(1):53-60. PubMed ID: 27783866
    [Abstract] [Full Text] [Related]

  • 4. De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naïve ALK rearranged lung cancers.
    Lucena-Araujo AR, Moran JP, VanderLaan PA, Dias-Santagata D, Folch E, Majid A, Kent MS, Gangadharan SP, Rangachari D, Huberman MS, Kobayashi SS, Costa DB.
    Lung Cancer; 2016 Sep 15; 99():17-22. PubMed ID: 27565908
    [Abstract] [Full Text] [Related]

  • 5. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.
    Doebele RC, Pilling AB, Aisner DL, Kutateladze TG, Le AT, Weickhardt AJ, Kondo KL, Linderman DJ, Heasley LE, Franklin WA, Varella-Garcia M, Camidge DR.
    Clin Cancer Res; 2012 Mar 01; 18(5):1472-82. PubMed ID: 22235099
    [Abstract] [Full Text] [Related]

  • 6. Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer.
    Kim S, Kim TM, Kim DW, Go H, Keam B, Lee SH, Ku JL, Chung DH, Heo DS.
    J Thorac Oncol; 2013 Apr 01; 8(4):415-22. PubMed ID: 23344087
    [Abstract] [Full Text] [Related]

  • 7. Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.
    Facchinetti F, Loriot Y, Kuo MS, Mahjoubi L, Lacroix L, Planchard D, Besse B, Farace F, Auger N, Remon J, Scoazec JY, André F, Soria JC, Friboulet L.
    Clin Cancer Res; 2016 Dec 15; 22(24):5983-5991. PubMed ID: 27401242
    [Abstract] [Full Text] [Related]

  • 8. ALK inhibitors in the treatment of advanced NSCLC.
    Gridelli C, Peters S, Sgambato A, Casaluce F, Adjei AA, Ciardiello F.
    Cancer Treat Rev; 2014 Mar 15; 40(2):300-6. PubMed ID: 23931927
    [Abstract] [Full Text] [Related]

  • 9. Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions.
    Kato Y, Ninomiya K, Ohashi K, Tomida S, Makimoto G, Watanabe H, Kudo K, Matsumoto S, Umemura S, Goto K, Ichihara E, Ninomiya T, Kubo T, Sato A, Hotta K, Tabata M, Toyooka S, Maeda Y, Kiura K.
    Cancer Sci; 2018 Oct 15; 109(10):3149-3158. PubMed ID: 30053332
    [Abstract] [Full Text] [Related]

  • 10. Detection of an EML4-ALK fusion mutation secondary to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer: a case report.
    Ren KH, Qin WW, Wang Y, Peng JC, Hu WX.
    Ann Palliat Med; 2022 Jul 15; 11(7):2503-2509. PubMed ID: 35927783
    [Abstract] [Full Text] [Related]

  • 11. Afatinib Overcomes Pemetrexed-Acquired Resistance in Non-Small Cell Lung Cancer Cells Harboring an EML4-ALK Rearrangement.
    Kwon JH, Kim KJ, Sung JH, Suh KJ, Lee JY, Kim JW, Kim SH, Lee JO, Kim JW, Kim YJ, Lee KW, Kim JH, Bang SM, Kim S, Yoon SS, Lee JS.
    Cells; 2019 Nov 28; 8(12):. PubMed ID: 31795298
    [Abstract] [Full Text] [Related]

  • 12. Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report.
    Rossing HH, Grauslund M, Urbanska EM, Melchior LC, Rask CK, Costa JC, Skov BG, Sørensen JB, Santoni-Rugiu E.
    BMC Res Notes; 2013 Nov 26; 6():489. PubMed ID: 24279718
    [Abstract] [Full Text] [Related]

  • 13. Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond.
    Ou SH.
    Drug Des Devel Ther; 2011 Nov 26; 5():471-85. PubMed ID: 22162641
    [Abstract] [Full Text] [Related]

  • 14. Resistance to Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK Rearrangement: Mechanisms, Treatment Strategies and New Targeted Therapies.
    Casaluce F, Sgambato A, Sacco PC, Palazzolo G, Maione P, Rossi A, Ciardiello F, Gridelli C.
    Curr Clin Pharmacol; 2016 Nov 26; 11(2):77-87. PubMed ID: 27138017
    [Abstract] [Full Text] [Related]

  • 15. Management and future directions in non-small cell lung cancer with known activating mutations.
    Gerber DE, Gandhi L, Costa DB.
    Am Soc Clin Oncol Educ Book; 2014 Nov 26; ():e353-65. PubMed ID: 24857124
    [Abstract] [Full Text] [Related]

  • 16. Identification and characterization of ALK kinase splicing isoforms in non-small-cell lung cancer.
    de Figueiredo-Pontes LL, Wong DW, Tin VP, Chung LP, Yasuda H, Yamaguchi N, Nakayama S, Jänne PA, Wong MP, Kobayashi SS, Costa DB.
    J Thorac Oncol; 2014 Feb 26; 9(2):248-53. PubMed ID: 24419423
    [Abstract] [Full Text] [Related]

  • 17. Overcoming EGFR Bypass Signal-Induced Acquired Resistance to ALK Tyrosine Kinase Inhibitors in ALK-Translocated Lung Cancer.
    Miyawaki M, Yasuda H, Tani T, Hamamoto J, Arai D, Ishioka K, Ohgino K, Nukaga S, Hirano T, Kawada I, Naoki K, Hayashi Y, Betsuyaku T, Soejima K.
    Mol Cancer Res; 2017 Jan 26; 15(1):106-114. PubMed ID: 27707887
    [Abstract] [Full Text] [Related]

  • 18. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.
    Katayama R, Shaw AT, Khan TM, Mino-Kenudson M, Solomon BJ, Halmos B, Jessop NA, Wain JC, Yeo AT, Benes C, Drew L, Saeh JC, Crosby K, Sequist LV, Iafrate AJ, Engelman JA.
    Sci Transl Med; 2012 Feb 08; 4(120):120ra17. PubMed ID: 22277784
    [Abstract] [Full Text] [Related]

  • 19. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
    Katayama R, Sakashita T, Yanagitani N, Ninomiya H, Horiike A, Friboulet L, Gainor JF, Motoi N, Dobashi A, Sakata S, Tambo Y, Kitazono S, Sato S, Koike S, John Iafrate A, Mino-Kenudson M, Ishikawa Y, Shaw AT, Engelman JA, Takeuchi K, Nishio M, Fujita N.
    EBioMedicine; 2016 Jan 08; 3():54-66. PubMed ID: 26870817
    [Abstract] [Full Text] [Related]

  • 20. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK.
    Katayama R, Khan TM, Benes C, Lifshits E, Ebi H, Rivera VM, Shakespeare WC, Iafrate AJ, Engelman JA, Shaw AT.
    Proc Natl Acad Sci U S A; 2011 May 03; 108(18):7535-40. PubMed ID: 21502504
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.